Calibr at Scripps Research
Arnab Chatterjee's work experience began in 1997 as an Analyst at Andersen Consulting. In 1998, they became a Graduate Student in Chemistry at Caltech until 2002. From 2002 to 2012, Chatterjee served as a Group Leader at GNF, Novartis. In 2012, they joined Calibr at Scripps Research as a Principal Investigator until 2014 when they became the Director of Medicinal Chemistry. In 2017, Chatterjee was promoted to Vice President of Medicinal Chemistry at Calibr at Scripps Research.
Arnab Chatterjee completed their education with a Ph.D. in Chemistry from Caltech during the years 1998 to 2002. Prior to that, they obtained a BA degree from Northwestern University from 1993 to 1997, majoring in Chemistry and Economics.
Calibr at Scripps Research
1 followers
The California Institute for Biomedical Research (Calibr) is a first-of-its-kind, nonprofit translational research institute dedicated to accelerating the next generation of medicines. Affiliated with Scripps Research—among the most innovative institutes worldwide—we spearhead drug discovery from a steady flow of pioneering science. Our self-sustaining model encourages broad and bold exploration with far-reaching goals, yet rapid transition of our most successful, high-impact programs into the clinic. We pursue audacious and imaginative ideas—bridging scientific and technological advances to develop new medicines for unmet medical needs. Our pipeline programs range from cancer to infectious diseases and from discovery to early clinical trial stages, all aimed at preventing disease and healing humans around the world. We bring together leaders in research, drug development, and business to answer important biological questions and develop new interventions to treat, cure, and prevent disease. Our infrastructure and expertise extend from high-throughput screening and protein engineering to pharmacology and clinical development. Calibr’s research space includes a newly renovated 35,000 square foot facility in La Jolla, CA, which houses over 100 interdisciplinary scientists and staff with state-of-the-art instrumentation. This infrastructure, combined with Calibr’s drug discovery expertise, enables projects rooted in novel therapeutic mechanisms to progress from the laboratory through preclinical development and ultimately to the clinic through commercial, federal, or foundation partnerships.